M	essa	ge	١
IVI	essa	ĸ١	

From:	PsBethell [/O=EXCHANGE	LABS/OU=EXCHANGE AI	OMINISTRATIVE GROUP			
		RECIPIENTS/CN=6F0A17	35F9834B5CA9C02D2016D42	2E9F-PSBET	HELL]	
Sent:	<u>12/07/2021 14:0</u> 1:03					
To:	NR [/o=Exc	nangeLabs/ou=Exchange	Administrative Group	:		
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=97760692	a16242188c590cbc44f1520c	:-[,	NR	
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup	!	1	
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=162eb2e6	786d44a5bd81b35441bc46c	g NR	Hayward, Davi	d
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup	'	-	
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=1efc6db5l	o2264126b120a6adae3ba48f	-DHayware	e]; Taylor, Charlo	otte
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup	!		7
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=4b2b7c4a	466b4efba718ba461283cf72	-CTaylor5];	NR	j
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup _i			
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=67575284	a2894139bb0dcfafcabfff5	N	R	
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup	r		
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=625d99e6	f6a646a1991536f1a8dd539b	NR NR	Van Tam, Jonat	:han
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup			
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=d29c846f	:8fa4678b419c6f0dc3836f3-J	IVanTam]		
CC:	TherapeuticsTaskforce [/c	=ExchangeLabs/ou=Exc	hange Administrative Group			
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=77a5c56e	13f947018f6f06c562730878-	Therapeuti	c]; Antivirals Ta	skforce
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup			
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=86a672bc	2cc5435a89749fc6e35bfc83-	AntiviralsT]; Squire, Laura	
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup			
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=e33d604f	f1f94c1b800904b6e8829776	-LSquire1];	ŊR	
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup _F .			
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=bc7c2560	8ffd4d0789c52cd91a437f8ta	NR j	Shielding Policy	
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup			
	(FYDIBOHF23SPDLT)/cn=f	Recipients/cn=09974283	462a4f23b1d9852172d1038	3-Shielding	P]; PsBethell	
	[/o=ExchangeLabs/ou=Ex	change Administrative G	roup			
	(FYDIBOHF23SPDLT)/cn=F	Recipients/cn=6f0a1735 ⁻	9834b5ca9c02d2016d42e9f	-PsBethell]		
Subject:	RE: (FT) Meeting with Lor	d Bethell to discuss Imm	uno-compromised and vacci	ne antibodi	es	
Hi everyone,						
in seem that the basis of the samesta						
Please see a r	eadout of the meeting w	ith Baroness Brinton	Lord Walney and the bloo	d cancer o	harity renrese	ntatives
on Wednesda		in baroness brinton,	Lora Wanney and the bloo	a caricer c	riditty represe	intatives
on wednesu	<u>y.</u>					
07/07/2024						
07/07/2021	, n		ND	_		NP
Attendees: P	S(I), NR Jo	nathan Van Tam,	NR	, Baroness	Brinton (BB)	NR

Action: JVT and PS(I) to discuss with colleagues and Ministers about who could fill the role of SRO on the immunocompromised.

- PS(I) introduced and noted his commitment to this issue.

NR

NR

- JVT made introductory remarks and summarised the key issues in this area. He noted that covid will remain prevalent in the population, and that therefore those who are immunocompromised and CEV are concerned. JVT noted the upcoming readout from the OCTAVE study in September, and noted that the JCVI will likely prioritise the immunocompromised for booster vaccinations.
- JVT noted the ongoing work on prophylactic antibodies.
- BB thanked JVT and noted that she would like to run through the issues in the paper she had sent up.
- BB noted that she would like to know who the clinical lead is for this work? Who is leading the policy on how to protect the immunocompromised? Is there a responsible Minister?

David Hayward, Lord Walney,

- PS(I) noted that he has had several meetings with Lord Mendelsohn and the charities represented on this call, as has Minister Zahawi, and noted that he is committed to this agenda.
- JVT added that he believes that there is a requirement for a clinical lead on the immunocompromised. This person needs to be able to pick up work on shielding, therapeutics, antibodies, and the vaccine agenda. There currently isnt anyone who is able to step into this space, and this is something that needs to be fixed. There needs to be further discussion with Ministers, but there is currently a gap.
- NR noted that we have to live with this virus, and there is a need for a clear strategy from Government about how we can support CEV individuals in the long term- such as mental health support and guidance for employers. This issue cuts across many areas in terms of employment, benefits, and financial support as well as medical support.
- JVT agreed and noted that the Government offer is not yet clear enough for the immunocompromised. There has been pressure to tackle the immediate issues of the virus, but now this issue is coming to a head, and it needs to be tackled.
- GP noted that on the issue of communication from Government- there are those living with conditions who are not in frequent contact with their GP. We need more widespread communication to immunocompromised individuals.
- PS(I) noted that this is why data sharing is vital, as this is the only way that we can know who we need to contact. PS(I) asked for GP's support on the GP data agenda.
- GP agreed that she would be happy to support this.
- JVT noted that there is a communications package coming from PHE that will be important in this space.
- BB noted that another key concern of the groups represented on the call is the lack of communication with the immunocompromised. People in this position feel as though they are being left behind by government policy, and would like reassurance from the Government.
- PS(I) said that this message was received loud and clear, and that the team recognises the challenge and that he and JVT would discuss this in more detail.

Many thanks,				
NR				
,	; 			
NR Private Secretary	I&S			
, ,	,			
Box times for Lord Bethell: Mon-Thu	irs 2nm Friday 12nm			
box times for Lord Bethell. Mon-The	ars zpm, rriday izpm			
Original Appointment				
From NR On Behalf Of DH	ll ordsDiary			
	Lorusbiary			
Sent: 29 June 2021 12:04	NP	<u></u>	ND	<u>-</u>
To: DHLordsDiary; Lord Bethell;	BRINTON, Barı, 'BRINTON', Barı	oness Not Relevant	NR	
i alender com	TI LIAZATNIENZI LIKAGE	GAN OF COTES Baroness:	NR	; Hayward,
NR MENDELSOHN	N, Lord; WALNEY, Lord; MOF	COAIN OF COTES, Daroness,		
David; Taylor, Charlotte;	N, Lord; WALNEY, Lord; MOF	Van Tam, Jonathan)	
David; Taylor, Charlotte; Cc: TherapeuticsTaskforce; Antivirals	NR	Van Tam, Jonathan	1	
David; Taylor, Charlotte;	NR	Van Tam, Jonathan	<u></u>	
David; Taylor, Charlotte; Cc: TherapeuticsTaskforce; Antivirals	NR Taskforce	Van Tam, Jonathan NR	<u> </u>	
David; Taylor, Charlotte; Cc: TherapeuticsTaskforce; Antivirals NR Shielding Policy	NR Taskforce	Van Tam, Jonathan NR promised and vaccine antibodic	<u> </u>	
David; Taylor, Charlotte; Cc: TherapeuticsTaskforce; Antivirals NR Shielding Policy Subject: (FT) Meeting with Lord Beth	NR Taskforce	Van Tam, Jonathan NR promised and vaccine antibodic	<u> </u>	
David; Taylor, Charlotte; Cc: TherapeuticsTaskforce; Antivirals NR Shielding Policy Subject: (FT) Meeting with Lord Beth When: 07 July 2021 10:30-11:00 (UTG	NR Taskforce	Van Tam, Jonathan NR promised and vaccine antibodic	<u> </u>	

Microsoft Teams meeting

Join on your computer or mobile app

Click here to join the meeting